Browse the evidence

Semaglutide is associated with a statistically significant signal of disproportionate reporting for depressive disorders in real-world pharmacovigilance data, whereas liraglutide and tirzepatide show no such signal.

If you are taking semaglutide, be aware that real-world data shows a higher reporting rate of depression compared to other GLP-1RAs like liraglutide or tirzepatide. This does not mean the drug definitely causes depression, but it suggests you should monitor your mood, especially if you are female. Discuss any mood changes with your doctor, as they may consider drug-specific monitoring.

GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide) are associated with statistically significant signals for otolaryngologic adverse events, specifically GERD, Medullary Thyroid Carcinoma (MTC), and Papillary Thyroid Carcinoma (PTC), across all approved drugs.

If you take a GLP-1 drug like Ozempic or Wegovy, be aware that reports of acid reflux (GERD) and thyroid issues (MTC/PTC) are significantly higher than background noise in the FDA database. You should discuss these risks with your doctor and monitor for symptoms like persistent heartburn or neck lumps, but do not stop medication without medical advice.

Semaglutide and Liraglutide show significant signals for specific otolaryngologic adverse events including anosmia, dysgeusia, Bell's palsy, and tinnitus, which are not as strongly or consistently reported with other GLP-1 RAs.

If you take Semaglutide or Liraglutide and experience loss of smell, taste changes, ringing in the ears, or facial weakness (Bell's palsy), these are reported side effects. Inform your healthcare provider, as these may require management adjustments.

Use of GLP-1 receptor agonists (semaglutide and tirzepatide) is associated with an increased risk of alopecia, potentially mediated by rapid weight loss-induced telogen effluvium or direct receptor interaction in hair follicles.

If you are taking semaglutide or tirzepatide and notice increased hair shedding, do not panic. This is likely telogen effluvium caused by rapid weight loss or metabolic stress, which is usually reversible. Ensure you are eating enough protein and nutrients. Talk to your doctor; they may adjust your plan or provide reassurance, but stopping the medication abruptly is rarely necessary unless the shedding is severe.

GLP-1 receptor agonists do not exacerbate psychotic symptoms in schizophrenia and provide metabolic benefits, but have not demonstrated consistent effects on core psychiatric symptomatology.

For people with schizophrenia, GLP-1 medications are safe and help with weight gain caused by antipsychotics, but they do not treat the psychosis itself. Do not expect them to improve hallucinations or cognitive function. They are a tool for metabolic health, not psychiatric symptom management in this population.

GLP-1 receptor agonists (semaglutide, tirzepatide) are effective for weight loss in the general population but demonstrate attenuated efficacy and unclear safety profiles specifically in breast cancer patients, particularly those receiving endocrine therapy.

If you have breast cancer and are taking hormonal therapy (like aromatase inhibitors), GLP-1 drugs like Semaglutide or Tirzepatide will likely help you lose weight, but not as much as they do for people without cancer. You should expect roughly half the weight loss seen in the general population. Discuss this with your oncologist, as safety data in your specific group is still being gathered.

Oral delivery of GLP-1 analogs (semaglutide, exenatide, dulaglutide) using liposomes containing tetraether lipids (TELs) and cell-penetrating peptides (CPPs) significantly increases cellular uptake in intestinal epithelial models compared to free peptides or conventional liposomes.

This research suggests a promising future where GLP-1 drugs (like Ozempic or Wegovy) could be taken orally using advanced liposome technology, potentially replacing injections. Currently, this is pre-clinical data showing high uptake in cell models, not a available product.

Subcutaneous administration of a semaglutide-rosuvastatin-lipid conjugate nanoparticle (SRLC NP) formulation significantly reduces body weight and improves liver function markers in high-fat diet-induced obese mice compared to conventional semaglutide or individual components.

This research describes a novel experimental nanoparticle formulation combining semaglutide with a statin-lipid conjugate. In obese mice, this specific formulation led to significant weight loss and liver health improvements compared to standard treatments. However, this is preclinical data; it is not a current treatment option for humans, and the safety and efficacy in people remain unproven.

Dihydromyricetin (DHM) supplementation improves insulin resistance and glucose tolerance in high-fat diet-induced mice by modulating gut microbiota to increase chenodeoxycholic acid (CDCA), which inhibits farnesoid X receptor (FXR) expression in intestinal L cells, thereby increasing glucagon gene (Gcg) mRNA expression and enhancing glucagon-like peptide-1 (GLP-1) secretion.

This research suggests that Dihydromyricetin (DHM), a compound found in plants like Ampelopsis grossedentata, may help improve insulin sensitivity and blood sugar control by changing gut bacteria to produce more beneficial bile acids (CDCA). This process boosts GLP-1, a hormone that helps regulate blood sugar. While this was shown in mice fed a high-fat diet, it points to the importance of gut health in metabolic function. For humans, this implies that dietary sources of DHM or gut-health-supporting strategies might be a complementary approach to managing insulin resistance, though human dosing and efficacy are not yet established.

Dysregulation of hypothalamic nuclei (specifically AgRP and POMC neurons in the arcuate nucleus) is a primary driver of obesity and type 2 diabetes through mechanisms involving insulin resistance, hyperphagia, and disrupted glucose sensing.

Metabolic diseases like obesity and diabetes are not just about willpower or peripheral fat storage; they involve critical signaling centers in the brain (the hypothalamus). When these signals (like leptin and insulin) are disrupted, it drives hunger and insulin resistance. This understanding supports the use of therapies that target these central pathways, such as GLP-1 receptor agonists, to help restore metabolic balance.

AgRP neuron hyperactivity contributes to chronic insulin resistance and obesity by inducing brown adipose tissue-derived myostatin expression, which systemically inhibits insulin signaling in skeletal muscle and white adipose tissue.

This mechanism explains why some individuals with obesity struggle with insulin resistance beyond just fat mass. It suggests that targeting the AgRP-myostatin pathway could be a therapeutic strategy, although current treatments focus more broadly on GLP-1 and MC4R pathways.

Semaglutide 2.4 mg use is associated with significant side effects, including gastrointestinal distress and rare but severe complications like pancreatitis.

Be prepared for gastrointestinal side effects, especially when starting or increasing the dose. These often subside, but severe symptoms like pancreatitis require immediate medical attention.

Baseline gut microbiome composition predicts the efficacy of semaglutide and empagliflozin in reducing HbA1c, whereas the drugs themselves do not significantly alter microbial diversity or composition.

If you are starting semaglutide or empagliflozin for Type 2 Diabetes, your current gut bacteria might predict how much your blood sugar (HbA1c) will drop. The drugs themselves don't seem to drastically change your gut diversity, but knowing your baseline microbiome could help personalize your treatment. This is still early research, so discuss testing options with your doctor.

Phentermine is generally avoided in older adults due to risks of falls, anxiety exacerbation, and cardiovascular side effects, despite its efficacy in younger populations.

Phentermine is rarely recommended for older adults because it can cause dizziness (increasing fall risk), worsen anxiety, and strain the heart. It is generally avoided in this age group due to multiple comorbidities.

Tirzepatide administration is associated with a high frequency of gastrointestinal adverse events (nausea, diarrhea, vomiting) and injection-site reactions, with a median time to onset of 26 days, occurring predominantly during the dose-escalation phase.

If you start Tirzepatide, expect gastrointestinal issues like nausea or diarrhea, especially in the first month. These are common reasons for stopping treatment. Starting at the lowest dose (5mg) might help you tolerate the medication better, as higher doses are linked to later but potentially more severe onset of side effects. Monitor your symptoms closely during the first few weeks.

Older adults (≥65 years) experience adverse events from Tirzepatide significantly earlier (median 12 days) than younger adults (median 31 days), suggesting heightened sensitivity or earlier symptom reporting in this demographic.

If you are over 65 and start Tirzepatide, be extra vigilant in the first two weeks. Side effects like nausea or dizziness may hit you much sooner than they would for a younger person. Report any severe symptoms to your doctor immediately, as discontinuation rates are higher in this age group.

GLP-1 receptor agonist use is associated with an increased risk of hair loss (alopecia, telogen effluvium), with incidence potentially correlated with the magnitude of weight loss.

If you are using a GLP-1 agonist (like Ozempic or Mounjaro) and notice increased shedding or thinning, this is a known potential side effect, often linked to rapid weight loss or hormonal shifts. It does not happen to everyone, and in some cases, hair regrowth has been observed. Do not stop your medication abruptly without consulting your doctor; discuss monitoring strategies or temporary pauses if the hair loss is severe.

Therapeutic inhibition of myostatin using inhibitors or antibodies is a potential treatment for muscle-wasting disorders like Duchenne muscular dystrophy, sarcopenia, and cachexia, but long-term safety and functional integrity are concerns.

Myostatin inhibitors are experimental treatments for serious muscle-wasting diseases. They are not available or recommended for healthy individuals. If you have a wasting disorder, consult a specialist about clinical trials. Do not attempt to self-administer myostatin blockers.

Personalized nutrition does not significantly reduce fasting blood glucose compared to control diets in adults with prediabetes or type 2 diabetes.

While personalized nutrition improves HbA1c and postprandial responses, it may not significantly lower fasting blood glucose compared to standard diets in the short term. Patients should focus on overall glycemic control (HbA1c) rather than just fasting numbers.

Tilorone attenuates high-fat diet-induced hepatic steatosis and improves glucose tolerance in mice by enhancing BMP9-Smad1/5/8 signaling and upregulating PPARγ expression.

This preclinical study suggests that tilorone, administered via intraperitoneal injection, can reduce liver fat and improve glucose metabolism in mice on a high-fat diet by activating specific signaling pathways. However, as this is an animal study using a synthetic small molecule administered via injection, it does not currently provide a direct, actionable protocol for human dietary or lifestyle intervention. Clinical trials are required to determine efficacy and safety in humans.

Liraglutide is associated with higher rates of anxiety and medication switching compared to Tirzepatide and Semaglutide.

If you have a history of anxiety, Liraglutide might not be the best choice, as this study found it was associated with higher anxiety rates and more medication switches compared to Tirzepatide and Semaglutide. Tirzepatide may offer a better balance of efficacy and tolerability for you.

GLP-1 receptor agonists are associated with reduced risks of various psychiatric disorders, including substance use disorders, suicidal ideation, and dementia, suggesting potential neuroprotective benefits beyond weight management.

While GLP-1RAs are primarily used for weight loss, emerging large-scale data suggests they may also reduce the risk of certain psychiatric conditions like dementia and substance use disorders. However, these benefits are observational, and more research is needed to confirm if GLP-1RAs directly cause these improvements or if other factors are involved.

The association between GLP-1 RAs and reduced cancer risk is not uniform across the class; liraglutide and semaglutide show reduced risk, while dulaglutide shows a neutral association.

While the class as a whole does not increase cancer risk, the protective effect may vary by drug. Liraglutide and semaglutide show signals of reduced risk, whereas dulaglutide shows a neutral effect. This suggests that the choice of GLP-1 RA might matter for long-term oncological safety, though more research is needed.

GLP-1 receptor agonists (GLP-1RAs) used for weight management and obesity are associated with a significantly higher risk of psychiatric adverse events, including suicidal behavior, panic attacks, and depressive disorders, compared to their use in diabetes treatment.

If you are using a GLP-1 medication (like semaglutide or tirzepatide) for weight loss, be aware that reports of mood changes, including anxiety, panic, or suicidal thoughts, are higher in weight management users than in diabetes users. Discuss these risks with your doctor before starting. If you experience sudden mood changes, contact your provider immediately. This does not mean everyone will experience this, but it is a known signal to monitor.